Portal de Periódicos da CAPES

Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells

2018; Society for Free Radical Research Japan; Volume: 63; Issue: 2 Linguagem: Inglês

10.3164/jcbn.17-64

1880-5086

Noriyuki Kitagawa, Masahide Hamaguchi, Saori Majima, Takuya Fukuda, Toshihiro Kimura, Yoshitaka Hashimoto, Muhei Tanaka, Masahiro Yamazaki, Naoto Nakamura, Michiaki Fukui,

Neuropeptides and Animal Physiology

Dipeptidyl peptidase-4 (DPP-4) is a critical molecule for the metabolism of incretins. In addition, DPP-4 is known as CD26, the receptor of T cells, and plays important role in activation of T cells. Recently, DPP-4 inhibitors (DPP4i) are reported to have several immunologic effects beyond glycemic control. DPP4i seem to have anti-inflammatory effects in patients with type 2 diabetes. This might be direct effects on T cells. However, the close mechanism is not clear. To evaluate the possibility, we performed ex vivo assays by using primarily human CD4+ T cells (CD4) and CD8+ T cells (CD8). We purified primary naïve CD4 and CD8 from human peripheral blood. Then, we evaluated the effect of DPP4i on the proliferation of naïve T cells and the cytokine production in ex vivo experiments. The proliferation of CD4 and CD8 were suppressed by adding DPP4i in a dose dependent manner. However, DPP4i did not inhibit cytokine production from CD4. It was revealed by phospho-flow that the T cell receptor (TCR) signaling was attenuated in the presence of DPP4i. Taken together, DPP4i modulated TCR signaling, which contributed to attenuate the proliferation of CD4 and CD8. DPP4i have adverse effects for the proliferation of human T cells.